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GBD  Global burden of disease
DALY  Disability adjusted life-year
YLDs  Years lived with disability
YLLs  Years of life lost
SDI  Socio-demographic index
HAQ  Healthcare access and quality
BMI  Body mass index
UI  Uncertainty interval
Globally, the number of cancer cases increased from 18.3 million in 2007 to 24.5 million in  20171. Cancers also 
accounted for 9.6 million deaths in 2017, or 17% of all  deaths2. There are large inter-country variations in the 
incidence, mortality, years lived with disability (YLD), years of life lost (YLL) and disability adjusted life years 
(DALYs) for all types of  cancers1. Therefore, up-to-date statistics on the incidence, mortality and DALYs for the 
different types of cancer is essential information for those making health-related decisions about priority areas, 
resource allocation, the effectiveness of prevention programmes and the need for additional research.
Kidney cancers are one of the most important cancers, due in part to the large economic burden of metastatic 
kidney cancer, which has been estimated to be $1.6 billion (2006 USD) in selected  countries3 and to globally 
account for more than 131,000 deaths and 342,000 incident cases each  year4. The etiology of kidney cancer 
is mainly unknown, but appears to be multifactorial in  nature5. A number of different risk factors have been 
studied, some of which are modifiable, thus creating an opportunity for primary prevention. The risk factors 
for kidney cancer have been categorized as: (a) life style risk factors—tobacco smoking, excess body weight, 
alcohol consumption, physical activity and diet; (b) medical history—hypertension, chronic kidney diseases, 
kidney stones, and diabetes mellitus; (c) environmental and occupational exposures—trichloroethylene and 
aristolochic acid; (d) genetic risk factors and  others5,6. The attributable burden of these risk factors have not been 
reported in previous research, although this information is very helpful in the development and prioritization 
of prevention programs.
Although, a number of studies have examined the burden of kidney cancer, to the best of our knowledge there 
have been no comprehensive articles published recently. In fact, previous studies have reported the incidence and 
mortality of kidney cancer only at a  global7 or regional  level8, and have not reported data from all the individual 
countries. This information is important, as countries may have completely different epidemiological patterns 
for kidney cancer and thus using global or regional-level data may be inappropriate. In addition, the most recent 
review paper on the global epidemiology of kidney cancer used older  data5. Furthermore, there have been no 
articles about kidney cancer from the latest release (September 2018) from GLOBOCAN (Global Cancer Inci-
dence, Mortality and Prevalence), which is another valuable source of information about the burden of  disease9. 
Therefore, this article reports the incidence, mortality and DALYs for kidney cancer and its attributable risk 
factors from 1990 to 2017 in 195 countries; by age, sex and socio-demographic Index (SDI).
Methods
Overview.  The Global Burden of Disease (GBD) study is a comprehensive research programme that studies 
the burden of disease across the world. GBD 2017 included estimates for 195 countries, grouped into 7 super-
regions and 21 regions, from 1990 to 2017. In total, 355 diseases and injuries, 282 causes of death and 84 risk fac-
tors were analyzed in this iteration of the GBD programme. Methods, including changes from previous updates, 
have been described in detail in the GBD 2017 capstone  manuscripts2,10,11. Furthermore, additional information 
on the data sources used, results, and analytical code can be found at https ://vizhu b.healt hdata .org/gbd-compa 
re/ and https ://ghdx.healt hdata .org/gbd-resul ts-tool. All rates are reported per 100,000 person-years, with 95% 
uncertainty intervals (UIs). The UIs take into account uncertainty due to measurement error, potential biases, 
and the modelling process. The estimates were computed using the mean estimate across 1,000 draws, and the 
95% UIs were specified on the basis of the 25th and 975th ranked values across all 1,000 draws. The GBD world 
population standard was used for the calculation of age-standardized  rates2.
Estimation  framework.  In accordance with version 10 of the International Classification of Diseases 
(ICD)2, all tumors coded as C64-C65.9, D30.0-D30.1, D41.0-D41.1 were considered to be kidney cancer. The 
estimates of kidney cancer mortality were calculated using vital registration system data (n = 18,557 site-years), 
vital registration-sample data (n = 761 site-years) and cancer registry data (n = 4,342 site-years)2. These data were 
provided by collaborators, or accessed via publicly available sources. Due to the sparsity of the mortality data, 
and the lack of vital registration systems in some locations with incidence data, GBD transformed incidence data 
into mortality estimates by multiplying the incidence data by independently modeled mortality-to-incidence 
ratios (MIR). The MIRs were modeled using data from locations where both mortality and incidence data for 
kidney cancer were available for the same year. The initial MIR model used a linear-step mixed-effects model 
with a logit link function, with the Healthcare Access and Quality Index (HAQ) as a predictive  covariate1,2. The 
estimates from this model were then smoothed over space and time and adjusted for time, space and age using 
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Spatio-Temporal Gaussian process  regression1. Mortality data from vital registration systems and the mortality 
estimates from cancer registry incidence data were combined and used as an input for a cause of death ensemble 
model (CODEm)2. The covariates in the CODEm are used to predict mortality, if data is sparse or missing. These 
covariates do not need to have a proven causal association, only robust evidence of an association with kidney 
cancer mortality is  required12. The covariates used in CODEm have been presented  elsewhere2. The CoDCorrect 
algorithm was used to adjust the sum of predicted single cause mortalities in an age–sex–state–year group, in 
order to be consistent with the results from the all-cause mortality  estimations2.
The incidence of kidney cancer was estimated by dividing the final mortality estimates by the MIR. The 
10-year prevalence of kidney cancer was computed by modelling survival of each incidence cohort using the 
MIR as a scalar to identify which countries fell between a theoretical best and a theoretical worst-case survival 
rate. Those cohort members who had survived more than 10-years were considered to be cured and these cases 
were assigned to one of two sequelae: diagnosis and primary therapy or the controlled phase of kidney cancer. 
Those in the cohort that had died within the last 10 years were divided into four sequelae, as presented in Table 1 
of the Online Appendix. The following durations of 5.3, 5.38, and 1 month were used for the diagnosis and pri-
mary therapy, metastatic and terminal phases, respectively. The remaining time was assigned to the controlled 
phase. Finally, each sequela-specific prevalence rate was multiplied with specific disability weights to estimate 
the sequela-specific YLDs.
The Socio-Demographic Index (SDI) was used to examine the association between country development 
and the burden of kidney cancer. The shape of the association between kidney cancer burden, measured as 
DALYs, with the SDIs of 21 regions and 195 countries and territories were determined using smoothing splines 
 models13. The observed burden of kidney cancer was compared with the level expected, based on the SDI values 
of the countries and regions.
The SDI ranges from 0–1, with 0 reflecting the lowest level of development and 1 the highest. SDI is comprised 
of the total fertility rate in women under 25 years old, mean education for those aged 15 and above, and lag 
distributed income per capita. The global maps were generated using R, software version 3.5.2.
Risk factors.  The proportion of kidney cancer DALYs attributable to high  BMI14,  smoking15 and occupa-
tional exposure to  Trichloroethylene16 were also calculated, as robust evidence exists of their association with 
kidney  cancer10. Using all available evidence, the relative risk and prevalence of exposure were estimated sepa-
rately for each risk factor and their corresponding population attributable fractions (PAFs) were estimated using 
the theoretical minimum exposure approach. The DALYs that were attributable to each risk factor were com-
puted by multiplying the total DALYs for kidney cancer by the PAFs for each risk factor–outcome pair for each 
age group, sex, location, and year. The definition of these risk factors and their relative risks for kidney cancer 
are fully described  elsewhere10.
Ethics approval and consent to participate.  Publicly available data were used in this report. The ethi-
cal committee of Shahid Beheshti University of Medical Sciences approved the project (IR.SBMU.RETECH.
REC.1397.1368). This study was based upon publicly available data and solely reflects the opinion of its authors 
and not that of the Institute for Health Metrics and Evaluation.
Consent for publication.  Not applicable.
Results
Global  level.  In 2017, there were 393.0 thousand (95% UI: 371.0–404.6) incident cases of kidney cancer, 
with an age-standardised rate of 4.9 (95% UI: 4.7–5.1). This increased by 4.7% (95% UI: − 1.1 to 11.7) between 
1990 and 2017, but this increase was not statistically significant. About 138.5 thousand (95% UI: 128.7–142.5) 
deaths occurred due to kidney cancer, with an age-standardised death rate of 1.7 (95% UI: 1.6–1.8). This death 
rate increased by 4.4% (95% UI: − 0.3 to 10.5) across the measurement period, but was not statistically signifi-
cant. Kidney cancer accounted for 3.3 million (95% UI: 3.1–3.4) DALYs in 2017, with an age-standardised rate 
of 41.1 (95% UI: 38.7–42.5). There was a decrease of 3.6% (95% UI: − 9.2 to 3.2) across the reporting period, but 
again this was not statistically significant (Table 1).
Regional  level.  At the regional-level, we found that High-income North-America [12.1 (95% UI: 11.6–
13.2)], Southern Latin America [11.6 (95% UI: 10.4–13.0)] and Eastern Europe [10.0 (95% UI: 9.5–10.5)] had 
the highest age-standardised incidence rates. In contrast, South Asia [1.9 (95% UI: 1.7–2.0)], Eastern Sub-Saha-
ran Africa [2.5 (95% UI: 2.1–2.9)] and Central Sub-Saharan Africa [2.7 (95% UI: 2.2–3.3)] had the lowest age-
standardised incidence rates. The age-standardised death rates were highest in Southern Latin America [4.3 
(95% UI: 3.9–4.7)], Central Europe [3.8 (95% UI: 3.3–4.0)] and Eastern Europe [3.8 (95% UI: 3.6–3.9)]. In con-
trast, South Asia [0.62 (95% UI: 0.56–0.66)], Eastern Sub-Saharan Africa [0.77 (95% UI: 0.67–0.88)] and Central 
Sub-Saharan Africa [0.85 (95% UI: 0.68–1.1)] had the lowest age-standardised death rates. The age-standardised 
incidence and death rates were higher for males in all of the GBD regions, although this difference was not sta-
tistically significant in all regions (Fig. 1a, b).
Most regions experienced an increase in age-standardised incidence rates, with South Asia [48% (95% UI: 
22–80)], Tropical Latin America [36% (95% UI: 28–45)] and High-income Asia Pacific [35% (95% UI: 13–50)] 
showing the largest increases. In contrast, the Caribbean [− 24% (95% UI: − 34 to 21)] and Southern Latin 
America [− 4% (95% UI: − 18 to 44)] showed non-significant decreases in their age-standardised incidence rates. 
The age-standardised death rates increased the most in East Asia [49% (95% UI: 5–75)], South Asia [39% (95% 
UI: 17–69)] and Central Europe [37% (95% UI: 20–45)]. The opposite was true for the Caribbean [− 22% (95% UI: 
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74,202) 12.2 (11.6, 13.2) 3.5 (− 3.6, 21.5)
19,048 (18,298, 




72.6 (68.9, 78) − 9.1 (− 14.9, 4)
Canada 4,364 (3,851, 4,843) 7.2 (6.4, 8) 35.2 (18.4, 52.2)
1988 (1751, 
2,168) 2.9 (2.6, 3.2) 20.1 (7.7, 31)
39,609 (35,572, 
43,294) 65.4 (58.9, 71.2) 11.3 (− 1, 21.8)
Greenland 9 (7, 10) 12.6 (10.7, 14.3) 9.2 (− 8.9, 31.8) 3 (3, 4) 5.2 (4.2, 5.8) − 2.9 (− 18, 15.5) 81 (69, 91) 113.1 (96.2, 127.6) − 9.3 (− 23.7, 8.4)
USA 64,469 (61,274, 70,161) 12.7 (12.1, 14) 2.6 (− 4.8, 21.7)
17,057 (16,377, 
18,210) 3.1 (3, 3.3)





73.4 (69.3, 79.6) − 10.6 (− 16.6, 3.4)
Australasia 3,873 (3,494, 4,320) 8.8 (7.9, 9.8) 28.1 (14.5, 45.3)
1588 (1,436, 
1739) 3.3 (3, 3.6) 0.1 (− 9.3, 14.3)
31,608 (28,621, 
34,962) 73.1 (66.3, 80.9)
− 3.5 (− 12.8, 
10.5)
Australia 3,249 (2,856, 3,689) 8.8 (7.7, 9.9) 31.9 (15.6, 52)
1,342 (1,196, 
1,497) 3.3 (2.9, 3.7) − 1 (− 12.4, 14.2)
26,566 (23,590, 
29,815) 73 (65.1, 82.2) − 4.2 (− 15, 10.9)




18,246) 4.4 (3.9, 4.8) 35.1 (13.1, 50.4)
8,974 (7,762, 




39.6 (35.9, 42.7) 11.8 (− 5.3, 21.2)
Brunei 29 (25, 34) 8.1 (7.1, 9.4) 58.2 (28.5, 95.6) 9 (8, 10) 2.9 (2.6, 3.5) 28.7 (3.2, 58) 255 (225, 299) 71.8 (63.6, 83.9) 30 (5.1, 57.2)
Japan 13,140 (11,485, 14,232) 4.4 (4, 4.9) 28.3 (11.8, 42.2)
7,387 (6,321, 




39.6 (36.3, 42.4) 5.5 (− 7.4, 13.1)
Singapore 226 (195, 259) 3.3 (2.8, 3.7) 25.7 (0, 48.5) 84 (75, 95) 1.2 (1.1, 1.4) 7 (− 13, 23.1) 2025 (1768, 2,301) 29.3 (25.7, 33.2) 3.7 (− 15.6, 19.4)




1669) 1.8 (1.6, 2) 104 (31, 140.5)
32,039 (27,744, 
36,254) 39.3 (34.1, 44.6) 70.1 (19, 100.8)
Western Europe 72,675 (65,478, 76,756) 9.2 (8.3, 9.7) 12.6 (5.6, 23.5)
30,325 (27,097, 




70.7 (65.6, 74.5) − 6.2 (− 11.1, 2)
Andorra 8 (6, 11) 6.7 (4.5, 8.5) 16.3 (− 13, 51.2) 4 (2, 5) 2.7 (1.8, 3.5) 1 (− 22, 24.8) 76 (51, 98) 60.6 (40.5, 77.4) − 4.7 (− 28.4, 22.1)
Austria 1,129 (1,018, 1,308) 7 (6.3, 8.4)
− 25.7 (− 34.8, 
− 0.2) 572 (526, 626) 3.1 (2.8, 3.5)
− 32.7 (− 39.3, 
− 13.4)
10,070 (9,207, 
11,596) 63 (57.4, 74.2)
− 39.3 (− 45.8, 
− 20)
Belgium 1,494 (1,341, 1663) 7.4 (6.7, 8.4) 5.7 (− 6.2, 24) 757 (685, 833) 3.2 (2.9, 3.5) − 6 (− 14.8, 6.9)
13,435 (12,190, 
14,971) 66.8 (60.4, 75.1)
− 13.6 (− 21.6, 
− 0.1)
Cyprus 74 (62, 87) 4.2 (3.5, 4.9) 93.5 (23.3, 146.1) 31 (26, 36) 1.6 (1.4, 1.9) 64.9 (0.9, 106.9) 672 (565, 782) 37.7 (31.6, 44) 58.8 (− 0.9, 99.4)
Denmark 880 (780, 975) 8.5 (7.5, 9.4) 58.1 (38.4, 77.8) 417 (370, 457) 3.7 (3.3, 4) 15.2 (2.9, 27.8) 8,165 (7,297, 8,970) 80 (71.7, 87.8) 8.5 (− 3.6, 21.5)
Finland 1,021 (909, 1,116) 9.4 (8.4, 10.3) 13.7 (1.6, 27.4) 443 (394, 482) 3.6 (3.3, 3.9)
− 2.7 (− 12.3, 
7.6)
8,185 (7,433, 
8,939) 77.5 (70.6, 84.5) − 9.7 (− 18.1, 0.1)
France 9,048 (7,620, 10,090) 7.8 (6.6, 8.8) 9.2 (− 2.6, 23.8)
4,583 (3,805, 
5,058) 3.2 (2.8, 3.6)
− 4.4 (− 13.3, 
5.2)
81,076 (69,457, 
89,681) 70.6 (61.2, 78)
− 10.9 (− 19, 
− 1.2)
Germany 17,693 (14,910, 20,045) 10.5 (9, 11.9) 0.8 (− 13.6, 19)
7,333 (6,149, 




79.2 (69.2, 89) − 8.9 (− 20.5, 6.4)
Greece 1,343 (1,211, 1,485) 6.8 (6.1, 7.6) 49.6 (31.7, 68.9) 682 (624, 738) 2.8 (2.5, 3) 26.9 (14.6, 39.5)
12,106 (11,051, 
13,185) 61.2 (56, 66.7) 22.7 (11.2, 35.1)
Iceland 61 (55, 68) 12.5 (11.3, 14) 26.2 (10.7, 43.8) 28 (26, 31) 5.2 (4.8, 5.7) 9.3 (− 2.1, 22.7) 555 (506, 613) 113.6 (103.8, 125.6) 4.2 (− 6.8, 16.7)
Ireland 555 (483, 630) 8.2 (7.1, 9.3) 33.9 (14.2, 56) 243 (214, 271) 3.4 (2.9, 3.7) 19.2 (3.5, 36.2) 5,019 (4,367, 5,657) 73.6 (64, 83.3) 9.2 (− 6.1, 24.8)
Israel 673 (598, 755) 6.3 (5.6, 7.1) 17.3 (2.4, 33.3) 312 (278, 344) 2.7 (2.4, 3) 3.1 (− 7.9, 14.1) 6,000 (5,419, 6,666) 56.6 (51, 63) − 2.6 (− 13.3, 9)
Italy 10,742 (9,244, 12,082) 8.9 (7.6, 10) 3.6 (− 10.1, 18.8)
4,311 (3,659, 
4,755) 2.9 (2.5, 3.2)
− 1.4 (− 11.2, 
8.1)
75,306 (65,578, 
83,159) 62.8 (54.7, 69.6)
− 13.5 (− 22.4, 
− 4.2)
Luxembourg 40 (33, 48) 4.4 (3.7, 5.3) 1.6 (− 16.8, 25.1) 18 (15, 21) 1.9 (1.6, 2.2) − 9.6 (− 24.9, 8.7) 357 (301, 424) 39.9 (33.6, 47.6)
− 17.1 (− 31.5, 
0.8)
Malta 56 (50, 62) 7.1 (6.4, 7.8) 28.1 (12.1, 47.8) 26 (24, 29) 2.9 (2.7, 3.2) 6.8 (− 5, 20.7) 508 (462, 559) 63.9 (58.2, 70.3) 5.3 (− 6.4, 19.4)
Netherlands 2,802 (2,422, 3,083) 9.1 (7.9, 10) 25.5 (9.9, 42.9)
1,340 (1,143, 
1,457) 3.9 (3.4, 4.3) 12.7 (3.8, 25.1)
25,485 (22,401, 
27,802) 82.8 (73.2, 90.1) 2 (− 6.9, 14.5)
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Portugal 1,269 (1,121, 1,447) 6.6 (5.8, 7.5) 9.6 (− 6.8, 29.5) 468 (422, 526) 2 (1.8, 2.2)
− 0.4 (− 11.5, 
11.2)
8,933 (8,043, 
10,093) 46.3 (41.3, 52.5)
− 13.3 (− 23.2, 
1.5)
Spain 9,810 (8,449, 10,990) 11.6 (10, 13.1) 33.5 (14, 53.2)
2,554 (2,217, 
2,789) 2.6 (2.3, 2.9) 30.9 (16.6, 43.4)
49,418 (42,877, 
54,345) 61 (52.9, 67.3) 19.7 (6.3, 31.8)
Sweden 1,390 (1,276, 1,497) 7.6 (6.9, 8.2) 4.7 (− 4.9, 23.8) 795 (726, 846) 3.7 (3.4, 4)
− 15.5 (− 21.7, 
− 1.5)
14,056 (12,851, 
15,046) 77.4 (70.8, 82.8) − 21.2 (− 27, − 8)
Switzerland 932 (827, 1,056) 6 (5.3, 6.8) 16.8 (− 1.1, 38.3) 419 (372, 465) 2.4 (2.1, 2.7) 0.2 (− 13.4, 14.5) 7,497 (6,652, 8,411) 49.3 (43.9, 55.5) − 9.3 (− 21.4, 5.7)
United Kingdom 10,597 (10,149, 11,084) 9.5 (9.1, 9.9) 33.1 (23.8, 41)
4,576 (4,372, 
4,762) 3.6 (3.5, 3.8) 15.4 (5.3, 21.8)
86,894 (83,373, 




10,168) 11.6 (10.4, 13)
− 4.2 (− 17.8, 
44.4)
3,495 (3,186, 





− 18.5 (− 28.6, 
18.1)
Argentina 6,094 (5,320, 6,975) 12 (10.5, 13.8) − 7.6 (− 23.5, 51)
2,292 (2025, 





− 20.7 (− 33, 
23.7)
Chile 2,269 (1967, 2,613) 10 (8.7, 11.5) 10.1 (− 6.4, 33.2) 911 (806, 1,020) 3.9 (3.5, 4.4) 4.6 (− 8.3, 21.5)
20,213 (17,775, 
23,120) 89 (78.2, 102.1) − 8 (− 19.8, 9.4)
Uruguay 731 (632, 882) 15.8 (13.6, 19) 11.3 (− 8.4, 64.3) 291 (254, 339) 5.5 (4.8, 6.5) 0.2 (− 14.7, 38.4) 6,478 (5,633, 7,630)
138.9 (120.5, 
163.3)
− 7.1 (− 21.2, 
30.8)
Eastern Europe 32,267 (30,307, 33,740) 10 (9.5, 10.5) 17.3 (4.1, 33.8)
12,953 (12,178, 





102.7) 13 (1.1, 27.2)















116.9) 192.9 (99.1, 255)




4,275) 103.4 (83.6, 120) 212 (99.4, 283.9)









Moldova 353 (316, 391) 6.8 (6.1, 7.6) 17.3 (0.5, 37.5) 129 (118, 141) 2.3 (2.1, 2.5) 31.5 (16.4, 49.6) 3,611 (3,298, 3,916) 70.1 (63.8, 76) 19.3 (6, 34.4)
Russia 22,657 (21,404, 23,939) 10.2 (9.7, 10.8) 4.8 (− 7, 20.5)
8,670 (8,269, 




94.5 (91.2, 98) − 1.9 (− 9.6, 10)
Ukraine 6,542 (5,855, 7,208) 9.5 (8.5, 10.6) 31.8 (3.8, 70.3)
2,958 (2,709, 




124.7) 35.3 (6.5, 74.7)
Central Europe 17,167 (14,768, 18,046) 8.6 (7.5, 9.1) 26.3 (9.6, 34)
8,099 (7,044, 




90.3 (80.1, 94.7) 20.8 (9.4, 27.4)
Albania 192 (155, 242) 4.9 (4, 6.1) 36.1 (6.5, 73.2) 83 (67, 103) 2 (1.6, 2.5) 52.2 (20.2, 91.6) 1914 (1548, 2,402) 50.1 (41, 61.5) 38.3 (10.1, 72.4)
Bosnia and 
Herzegovina 436 (375, 499) 7.6 (6.5, 8.7) 39.7 (6.1, 67.1) 186 (162, 212) 3.1 (2.8, 3.6) 68.3 (21.7, 96.4)
4,288 (3,739, 
4,867) 76.5 (66.8, 86.8) 55.7 (14.8, 82.3)




8,491) 63.8 (56.4, 70) 114.5 (81, 143.7)
Croatia 1,000 (790, 1,119) 12.3 (9.9, 13.8)
152.3 (60.5, 




7,460) 84.5 (72.6, 93)
150.1 (78.8, 
188.3)
Czech Republic 2,608 (2097, 2,895) 13.1 (10.7, 14.5) 20.8 (− 1.2, 36.5)
1,173 (954, 




130.6) 15.5 (− 1.9, 27.3)
Hungary 1738 (1566, 1926) 9.8 (8.8, 10.9)
− 23.5 (− 33.3, 
− 12.5) 788 (723, 853) 4.1 (3.8, 4.4)
− 11.9 (− 20.1, 
− 3)
16,557 (15,177, 
18,020) 96 (88.3, 104.6)
− 18.7 (− 26.6, 
− 9.6)
Macedonia 138 (116, 158) 4.5 (3.6, 5.2) 108.9 (14.2, 157.4) 53 (46, 61) 1.6 (1.4, 1.9) 120.4 (24.9, 169)
1,377 (1,154, 
1574) 45.7 (37.5, 51.9)
119.1 (21.8, 
165.6)
Montenegro 54 (46, 65) 5.7 (4.9, 6.7) − 0.2 (− 16.4, 21.8) 23 (20, 27) 2.3 (2, 2.7) 13.4 (− 4.1, 38.3) 528 (458, 624) 55.7 (48.5, 64.9) 4 (− 11.6, 24.9)
Poland 5,290 (4,596, 5,803) 8.1 (7.1, 8.9) 20.6 (9.1, 33.3)
3,171 (2,710, 




115.8) 6.2 (− 2.7, 17.4)
Romania 2,290 (2053, 2,536) 7.1 (6.4, 7.8) 26.7 (11.6, 44.1) 941 (870, 1,048) 2.7 (2.5, 2.9) 53.6 (39.1, 67.1)
22,473 (20,734, 
24,368) 72 (66.3, 78) 35 (22, 49.1)
Serbia 1,165 (933, 1,318) 7.9 (6.3, 9) 13.3 (− 5.2, 42.1) 524 (429, 586) 3.3 (2.7, 3.7) 29.3 (7.1, 60.9)
11,597 (9,294, 
12,985) 79.6 (62.5, 89.8) 15.8 (− 2.4, 42.8)
Slovakia 1,234 (652, 1,440) 14.1 (7.7, 16.5)
156.2 (10.7, 






105.1) 124.8 (0.2, 175.8)
Slovenia 318 (277, 359) 8.1 (7, 9.1) 44.8 (20.6, 67.4) 146 (125, 163) 3.4 (2.9, 3.8) 67.5 (40, 91) 2,873 (2,514, 3,208) 74.5 (65.5, 83) 48.2 (27.3, 68.3)
Central Asia 5,185 (4,844, 5,520) 6.3 (5.9, 6.7) 12.3 (− 7, 37.4)
1704 (1611, 
1791) 2.2 (2.1, 2.4) 25.6 (2.2, 55.7)
52,337 (49,287, 
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2,612) 59.1 (50.4, 64.5)
301.1 (144.6, 
391)
Azerbaijan 869 (723, 1,038) 8.3 (7, 9.8) − 1.6 (− 25.6, 34.7) 286 (238, 339) 2.9 (2.5, 3.5)
11.8 (− 16.7, 
58.9)
8,954 (7,515, 
10,555) 84.1 (71.1, 99.2) 2.5 (− 21.1, 39)
Georgia 371 (323, 420) 6.9 (6, 7.8) 36.7 (15.3, 62.2) 144 (128, 159) 2.5 (2.2, 2.8) 54.8 (34.4, 77.6) 3,783 (3,336, 4,235) 71.2 (63.2, 79.4) 45 (25.6, 66.4)
Kazakhstan 1,403 (1,254, 1566) 7.7 (6.9, 8.6)
− 10.7 (− 34, 
25.8) 490 (448, 536) 2.8 (2.6, 3.1) − 1.4 (− 27, 37.6)
13,958 (12,704, 
15,385) 76.3 (69.7, 83.7)
− 6.6 (− 31.1, 
29.3)
Kyrgyzstan 232 (195, 270) 4.6 (3.9, 5.2) 57.3 (9.8, 91.2) 71 (63, 81) 1.6 (1.4, 1.8) 68 (31.8, 94.4) 2,298 (1998, 2,646) 44.2 (38.8, 50.4) 64.2 (21.9, 93.5)
Mongolia 124 (106, 146) 5 (4.3, 5.8) 44.2 (− 5.6, 92.8) 39 (33, 45) 1.9 (1.5, 2.2) 61.2 (0.6, 109.1) 1,189 (1,035, 1,377) 46.8 (40.3, 53.7)
56.3 (− 1.5, 
102.8)
Tajikistan 389 (327, 453) 5.6 (4.8, 6.5) 13.2 (− 8.9, 43.9) 107 (93, 123) 1.8 (1.6, 2.2) 22.1 (− 1.7, 50.9) 3,989 (3,445, 4,558) 56.1 (48.8, 64.4) 16.6 (− 6.4, 44)
Turkmenistan 364 (314, 416) 8.1 (7.1, 9.2) 27.8 (3.8, 57.4) 113 (99, 127) 2.7 (2.4, 3.1) 40.2 (13.7, 69.4) 3,739 (3,294, 4,185) 82.1 (72.3, 91.7) 33.3 (9.1, 60)








14,577) 5.7 (5.4, 6) 28.5 (20.1, 44.5)
4,542 (4,308, 




52.4 (49.9, 55.4) 15.9 (9.3, 29.6)
Colombia 1879 (1611, 2,187) 3.6 (3.1, 4.2) 29.4 (8.6, 51.3) 637 (549, 720) 1.2 (1, 1.3) 21.1 (4.7, 37.6)
17,749 (15,141, 
20,137) 34 (28.9, 38.5) 17.6 (1.9, 34.1)
Costa Rica 246 (212, 280) 5 (4.3, 5.6) 73 (43.8, 110.2) 89 (78, 100) 1.8 (1.6, 2) 60.3 (36.7, 91.1) 2,285 (1999, 2,589) 46.2 (40.4, 52.1) 59.4 (35.8, 87.3)
El Salvador 209 (167, 270) 3.6 (2.9, 4.7) 38 (7.7, 76.3) 69 (57, 86) 1.2 (1, 1.5) 44.3 (16.6, 80.8) 1847 (1508, 2,307) 32.2 (26.2, 40.5) 25.1 (1.7, 54.7)
Guatemala 478 (413, 571) 3.7 (3.2, 4.3) 14.5 (− 5.1, 46) 132 (118, 152) 1.2 (1, 1.3) 13 (− 1.7, 34.9) 4,362 (3,891, 5,080) 32.9 (29.3, 37.9) 5 (− 8.5, 29.3)
Honduras 238 (175, 322) 3.4 (2.6, 4.6) 50.5 (10.5, 94.9) 71 (55, 93) 1.2 (0.9, 1.5) 53.4 (19.6, 96.1) 2,102 (1549, 2,842) 30 (22.8, 40.5) 23.7 (− 6.5, 56.7)
Mexico 8,279 (7,859, 8,694) 6.9 (6.5, 7.2) 39.1 (31.1, 47.1)
2,783 (2,658, 
2,911) 2.4 (2.3, 2.5) 31.9 (24.4, 38.8)
76,149 (72,453, 
79,896) 63.4 (60.4, 66.5) 24 (17.3, 30.3)
Nicaragua 166 (138, 226) 3.2 (2.7, 4.4) − 1 (− 21.3, 40) 50 (43, 69) 1.1 (0.9, 1.5) 2.4 (− 14.7, 39.3) 1542 (1,324, 2065) 29.8 (25.5, 40.6)
− 11.9 (− 26.6, 
23)
Panama 172 (151, 193) 4.4 (3.8, 4.9) 87.5 (59.2, 117.2) 59 (53, 65) 1.5 (1.3, 1.6) 69.6 (49.3, 88.8)
1582 (1,421, 
1752) 40.2 (36.1, 44.6) 71.2 (51, 91.8)
Venezuela 2096 (1741, 2,523) 7 (5.8, 8.4) − 3.8 (− 25, 61.6) 653 (548, 784) 2.3 (1.9, 2.8)
− 6.3 (− 24.6, 
42.6)
19,329 (16,215, 
23,065) 64.5 (54.4, 77.1)





3,162) 5 (4.4, 5.6) 6.4 (− 8, 24.6) 982 (844, 1,093) 1.8 (1.6, 2) 14 (0.8, 30.8)
25,816 (22,594, 
28,915) 46 (40.2, 51.3)
− 3.1 (− 15.9, 
11.9)
Bolivia 530 (415, 664) 5.6 (4.5, 7) 25 (− 10.3, 76.1) 176 (142, 217) 2.1 (1.7, 2.5) 32.6 (1.9, 74.7) 4,838 (3,824, 5,947) 50.9 (40.3, 62.7) 12.6 (− 18.6, 57)
Ecuador 757 (640, 872) 4.9 (4.2, 5.6) 28 (7, 66.9) 247 (218, 277) 1.7 (1.5, 1.9) 28.1 (12.1, 63.1) 6,865 (6,003, 7,734) 44.5 (39.1, 50.1) 16.9 (1.4, 48.8)
Peru 1542 (1,262, 1,840) 4.9 (4.1, 5.9) − 5 (− 23.7, 17.2) 558 (455, 652) 1.8 (1.5, 2.1) 5.1 (− 14.3, 26.9)
14,114 (11,645, 
16,629) 45.4 (37.4, 53.5)
− 13.3 (− 29.6, 
4.9)
Caribbean 2,310 (2052, 2,813) 4.7 (4.1, 5.7)
− 23.6 (− 34.4, 
21.4) 762 (696, 896) 1.5 (1.4, 1.8)
− 21.9 (− 30.2, 
16.4)
20,946 (18,796, 
25,112) 42.6 (38.1, 51.1) − 29 (− 37.9, 8)
Antigua and 
Barbuda 5 (4, 6) 4.9 (4.2, 6)
− 16.2 (− 31.8, 
32.8) 2 (1, 2) 1.6 (1.4, 1.9)
− 19.5 (− 31.6, 
18.9) 44 (39, 52) 45.1 (40.1, 53.6)
− 21.1 (− 33.1, 
17.5)
The Bahamas 25 (22, 30) 6.2 (5.4, 7.4) − 14.2 (− 29.2, 26.6) 7 (6, 8) 1.9 (1.7, 2.2)
− 20 (− 31.1, 
11.1) 223 (198, 259) 56.2 (49.9, 65.4)
− 21.4 (− 32.5, 
9.7)
Barbados 29 (25, 39) 7 (6, 9.5) − 24.1 (− 38.4, 26) 11 (9, 14) 2.3 (2, 3)
− 27.8 (− 38.7, 
12.8) 263 (230, 341) 63.4 (55.5, 81.9) − 29.7 (− 40.5, 9)
Belize 17 (15, 25) 5.4 (4.7, 7.8) 22.7 (− 2.1, 111.8) 4 (4, 6) 1.6 (1.4, 2.2) 13.6 (− 4.5, 80.8) 154 (137, 211) 48.2 (42.6, 66) 10.2 (− 7.7, 78.8)
Bermuda 7 (6, 8) 6.2 (5.4, 7.9) − 43.9 (− 54.2, − 11.8) 3 (2, 3) 2.3 (2, 2.8)
− 43.5 (− 51.5, 
− 15.4) 62 (55, 77) 58.9 (52.4, 72.9)
− 47.6 (− 54.9, 
− 21.2)
Cuba 843 (720, 1,045) 5.1 (4.4, 6.4) − 23.3 (− 38.1, 35.2) 315 (274, 375) 1.8 (1.5, 2.1)
− 20.8 (− 33.4, 
28.6)
7,741 (6,721, 
9,408) 47.5 (41.5, 57.6)
− 27.8 (− 39.3, 
22.7)
Dominica 6 (5, 7) 7 (6.1, 9.1) 9.2 (− 11.2, 76.2) 2 (2, 2) 2.1 (1.9, 2.7) − 1.1 (− 15.2, 50.2) 51 (46, 64) 65.5 (57.8, 81.3) 4.3 (− 10.8, 58.5)
Dominican 
Republic 286 (226, 451) 2.9 (2.3, 4.6)
− 24.4 (− 41.9, 
45.9) 86 (68, 127) 0.9 (0.7, 1.4)
− 17.3 (− 35.6, 
49.4)
2,636 (2,126, 
4,142) 27.2 (21.9, 42.6)
− 29.7 (− 44.5, 
32)
Grenada 6 (5, 7) 4.3 (3.7, 5.4) − 15.7 (− 32.4, 53.6) 2 (2, 2) 1.4 (1.2, 1.7)
− 18.3 (− 31.5, 
39.2) 51 (45, 63) 39.5 (34.9, 48.6)
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Guyana 36 (30, 44) 5.1 (4.3, 6.3) − 6.3 (− 25.3, 54.6) 9 (8, 11) 1.5 (1.3, 1.8)
− 12.8 (− 27.7, 
35.9) 317 (276, 377) 45.5 (39.6, 54)
− 13.9 (− 28.6, 
35)
Haiti 455 (329, 723) 5 (3.7, 7.7) − 25.2 (− 51.3, 20.2) 107 (79, 160) 1.5 (1.1, 2.1)
− 18.4 (− 43.1, 
15.5)
4,061 (3,086, 
6,168) 43.9 (33.6, 65.9)
− 31.5 (− 53.6, 
7.2)
Jamaica 110 (82, 175) 3.8 (2.9, 6.1) − 16.9 (− 42, 69.2) 33 (25, 49) 1.1 (0.9, 1.7)
− 25.6 (− 45.4, 
37.9) 938 (717, 1,399) 33 (25.4, 49.3)
− 24.1 (− 45.2, 
42.8)
Puerto Rico 248 (222, 280) 4.3 (3.8, 4.9) − 9 (− 23.7, 39) 105 (95, 115) 1.5 (1.4, 1.7) − 12.8 (− 24.5, 26.4)
2,252 (2024, 
2,496) 39.4 (35.4, 44.2)
− 15.4 (− 26.3, 
22)
Saint Lucia 9 (8, 12) 4.5 (3.9, 5.9) − 25.3 (− 40.8, 29.1) 3 (3, 4) 1.4 (1.3, 1.8)
− 28.8 (− 40.2, 
17.4) 84 (73, 107) 41.3 (36.2, 52.5)





7 (6, 9) 5.3 (4.6, 7) − 14.8 (− 34.1, 67) 2 (2, 3) 1.5 (1.3, 2)
− 23.8 (− 37.6, 
41.1) 59 (53, 77) 46.1 (41.1, 59.6)
− 20.9 (− 35.2, 
46.3)
Suriname 30 (25, 41) 5 (4.2, 6.9) − 12.6 (− 30.8, 52.9) 9 (8, 12) 1.5 (1.3, 2.1)
− 14.4 (− 28.8, 
42.2) 272 (236, 363) 45.7 (39.7, 60.7) − 20 (− 33.3, 33)
Trinidad and 
Tobago 93 (72, 145) 5.6 (4.3, 8.6)
− 36.9 (− 53.1, 
30.7) 29 (23, 43) 1.7 (1.3, 2.4)
− 41.4 (− 54.7, 
10.2) 833 (663, 1,219) 50.7 (40.4, 73.5)
− 40.8 (− 53.7, 
12.8)




12,216) 5 (4.8, 5.3) 36.1 (27.7, 44.9)
4,029 (3,809, 




46.7 (44.3, 48.6) 21.1 (14, 28.5)
Brazil 11,441 (10,833, 11,963) 5.1 (4.8, 5.3) 37 (28.3, 46.1)
3,945 (3,727, 




46.9 (44.4, 48.8) 21.8 (14.7, 29.4)
Paraguay 257 (208, 326) 4.5 (3.6, 5.7) 7.7 (− 16.6, 52.8) 84 (68, 108) 1.6 (1.3, 2) 6.9 (− 15.9, 51.5) 2,341 (1906, 2,934) 40.6 (33.1, 51.1)
− 0.4 (− 21.8, 
37.5)
East Asia 52,291 (46,830, 56,228) 2.8 (2.5, 3) 20.7 (− 9.5, 39.7)
18,634 (16,488, 




25.1 (22.5, 26.9) 20.7 (− 12.7, 38.7)
China 48,211 (43,259, 52,182) 2.7 (2.4, 2.9)
18.4 (− 11.1, 
37.9)
17,168 (15,361, 




24.6 (21.9, 26.5) 18.4 (− 14.6, 37)
North Korea 1,131 (748, 1757) 3.7 (2.5, 5.7)
15.8 (− 15.7, 
51.4) 313 (208, 486) 1 (0.7, 1.6) 20.6 (− 9.8, 52.4)
9,321 (6,158, 




2,332) 5.9 (4.5, 6.5)
136.9 (51.7, 




18,898) 48.7 (38.8, 52.7)
147.2 (70.1, 
175.6)
Southeast Asia 20,831 (17,706, 22,722) 3.3 (2.8, 3.6) 23 (5.9, 41.9)
5,975 (5,097, 




28.1 (23.8, 30.5) 28.2 (9.4, 47.6)
Cambodia 401 (308, 528) 3.1 (2.4, 4.1) 13.6 (− 21.7, 67.9) 111 (87, 144) 1 (0.8, 1.3) 29 (− 8.1, 78.5)
3,354 (2,615, 
4,303) 26 (20.3, 33.4)
17.9 (− 19.5, 
70.9)
Indonesia 7,406 (6,250, 8,437) 3.2 (2.7, 3.6) 37.9 (10.9, 68)
2088 (1747, 
2,391) 1 (0.9, 1.2) 64.4 (33.7, 92)
62,168 (51,970, 
70,541) 26.6 (22.4, 30.1) 42.1 (12.3, 76)
Laos 192 (139, 262) 3.7 (2.7, 5) 15.8 (− 27.2, 89.1) 47 (36, 62) 1.1 (0.8, 1.4) 33.7 (− 11.2, 96)
1654 (1,226, 
2,162) 30.9 (23.4, 40.3)
20.4 (− 21.4, 
97.7)
Malaysia 872 (718, 1,177) 3.3 (2.7, 4.3) 35.2 (5.2, 82.8) 295 (245, 389) 1.2 (1, 1.6) 47 (14.6, 99.9) 7,582 (6,238, 10,172) 28 (23.2, 37.2) 40.2 (9.1, 89.7)
Maldives 8 (7, 9) 2.5 (2.1, 2.9) − 22.2 (− 48.3, 35.3) 2 (2, 3) 0.9 (0.7, 1)
− 6.2 (− 33.8, 
36.1) 71 (62, 82) 21.7 (18.8, 24.9)
− 16.1 (− 44.8, 
42.8)
Mauritius 56 (50, 64) 3.6 (3.2, 4) 36 (15.8, 56.5) 18 (16, 20) 1.1 (1, 1.2) 43.5 (27.7, 60.3) 480 (435, 531) 30.6 (27.7, 33.5) 40.4 (24.9, 56.8)
Myanmar 2,128 (1661, 2,701) 4.4 (3.5, 5.6)
20.3 (− 21.2, 
80.2) 589 (463, 743) 1.3 (1.1, 1.7) 38.2 (− 4.6, 90.4)
17,704 (14,062, 
22,120) 36.5 (29.2, 45.5) 25.3 (− 16.9, 85)
Philippines 3,849 (3,044, 4,572) 4.4 (3.6, 5.1) 47.8 (19.8, 80.1) 918 (769, 1,051) 1.2 (1, 1.4) 54.1 (31.3, 80.3)
33,067 (27,040, 
37,956) 37 (30.8, 42.4) 50.9 (25.6, 75.8)
Sri Lanka 1592 (1,154, 1986) 6.3 (4.6, 7.8)
− 24.9 (− 43.8, 
0.1) 541 (384, 663) 2.2 (1.6, 2.7)
− 16.9 (− 35.5, 
7.5)
13,677 (9,934, 
16,943) 53.6 (39.7, 65.9)
− 19.5 (− 38.6, 
4.1)
Seychelles 6 (5, 7) 5.4 (4.4, 6.1) 79.6 (17.6, 117.9) 2 (2, 2) 1.8 (1.5, 2)
95.8 (26.6, 
132.3) 52 (42, 59) 46.8 (38.1, 52.6) 90.8 (23.6, 125.7)
Thailand 2,368 (1807, 2,710) 2.6 (1.9, 3) 17.4 (− 2.4, 40.1) 763 (594, 867) 0.8 (0.6, 0.9) 21.7 (4.2, 41.4)
20,556 (15,156, 
23,609) 22.7 (16.6, 25.9) 23.3 (5.1, 43.8)
East Timor 28 (17, 40) 3 (1.8, 4.2) 26.6 (− 28.4, 104.7) 8 (5, 11) 0.9 (0.6, 1.3)
54.2 (− 5.6, 
120.4) 243 (151, 350) 25 (15.7, 36.1)
31.9 (− 25.5, 
114.2)
Vietnam 1898 (1529, 2,344) 2 (1.6, 2.4)
12.6 (− 11.7, 
46.5) 585 (488, 708) 0.7 (0.6, 0.8) 20.8 (− 2, 56.4)
16,048 (13,078, 
19,619) 16.7 (13.7, 20.3) 18.2 (− 5.1, 51)
Oceania 266 (205, 354) 2.9 (2.3, 3.7) 9.4 (− 8, 28.9) 59 (46, 74) 0.9 (0.7, 1.1) 14.3 (0.5, 30.8) 2,285 (1784, 2,917) 24.4 (19.2, 30.9) 12.5 (− 3.1, 30.9)
American 
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of Micronesia 3 (2, 4) 3.6 (2.5, 4.7) 12 (− 18.4, 45.6) 1 (1, 1) 1.1 (0.8, 1.4) 16.7 (− 9.2, 46.2) 25 (18, 33) 30 (21.1, 39.1) 15.3 (− 14, 47.5)
Fiji 21 (17, 24) 2.5 (2.1, 3) 16.1 (− 12, 50.7) 5 (4, 6) 0.8 (0.7, 0.9) 16.3 (− 10.7, 50.6) 175 (146, 205) 21.1 (17.7, 24.6) 18.5 (− 8.8, 52.7)
Guam 10 (8, 11) 5.3 (4.4, 6.2) 8.5 (− 18.4, 48.7) 3 (3, 3) 1.7 (1.4, 1.9) 5.6 (− 20.4, 46.3) 87 (73, 101) 47 (39.4, 54.1) 11.3 (− 16.8, 51.7)
Kiribati 4 (3, 5) 4.3 (3.4, 5.2) 33.8 (1, 71.3) 1 (1, 1) 1.3 (1, 1.5) 39.7 (9.3, 71.2) 32 (25, 39) 36.5 (28.8, 43.7) 39.2 (6.7, 74.8)
Marshall Islands 2 (1, 3) 4.7 (3.5, 6.6) 28.8 (1.8, 65) 0 (0, 1) 1.5 (1.1, 2) 32.6 (8.3, 62.6) 17 (12, 23) 39.9 (29.4, 55.4) 32.7 (7.4, 64.8)
Northern Mari-
ana Islands 2 (2, 3) 4.3 (3.4, 5.2)
− 0.2 (− 25.4, 
30.9) 1 (1, 1) 1.5 (1.2, 1.8) 6 (− 19.7, 35.9) 22 (17, 27) 38.1 (30.4, 45.9) 3.6 (− 22.7, 35.1)
Papua New 
Guinea 182 (130, 260) 2.7 (2, 3.8) 6.3 (− 16.6, 34.2) 37 (27, 50) 0.7 (0.5, 1) 13.7 (− 6.7, 37.3)
1552 (1,144, 
2,125) 22.8 (16.7, 30.9) 9.7 (− 11.4, 34.8)
Samoa 3 (3, 4) 2.1 (1.7, 2.6) 2.6 (− 19.9, 31.4) 1 (1, 1) 0.7 (0.6, 0.9) 14.2 (− 8.9, 43.3) 27 (22, 33) 17.5 (14.2, 21.3) 3.9 (− 16.2, 28.9)
Solomon Islands 13 (8, 17) 2.9 (1.9, 3.9) 11.8 (− 13.3, 44.1) 3 (2, 4) 0.8 (0.6, 1.2) 15.4 (− 7.8, 44.9) 106 (70, 147) 23.9 (15.9, 32.8) 14.5 (− 9.6, 45.5)
Tonga 4 (3, 5) 4.1 (2.9, 5.7) 35.5 (3.3, 76.5) 1 (1, 1) 1.4 (1, 1.8) 35.8 (5, 74.9) 31 (22, 43) 35.5 (25.4, 48.6) 43.8 (10.6, 87.3)




16,227) 3.1 (2.7, 3.3) 25.9 (3.5, 56.6)
4,497 (3,911, 




28.7 (24.8, 30.7) 13.3 (− 7, 38.7)
Afghanistan 691 (386, 1,261) 3.7 (2.1, 6.1) 10.3 (− 27.2, 154.3) 142 (81, 231) 1.1 (0.6, 1.6) 4 (− 26.3, 91.8)
6,284 (3,636, 
10,835) 31.8 (18.2, 51.3)
− 3 (− 35.1, 
113.6)
Algeria 690 (557, 802) 1.9 (1.5, 2.2) 44.6 (20, 76.1) 216 (174, 248) 0.7 (0.5, 0.8) 29.7 (7.8, 59.6) 6,251 (5,132, 7,132) 17.3 (14.1, 19.8) 30.3 (8.8, 58.3)
Bahrain 39 (32, 46) 3.2 (2.7, 3.8) − 23.3 (− 36.6, − 3.1) 11 (10, 13) 1.3 (1.1, 1.4)
− 31.8 (− 43.1, 
− 14) 367 (313, 426) 30.3 (26.1, 34.5)
− 31 (− 42.2, 
− 13.4)
Egypt 2,121 (1698, 2,576) 2.7 (2.2, 3.3) 42.9 (13.8, 79.2) 523 (435, 621) 0.8 (0.7, 1) 40.9 (15.1, 73.7)
19,791 (16,429, 
23,176) 25 (21.3, 29.3) 26.9 (4, 52)
Iran 2,376 (1965, 2,632) 3.2 (2.6, 3.5) 35.7 (7.1, 70.6) 775 (640, 821) 1.2 (0.9, 1.2) 44.5 (24.6, 76.6)
21,874 (18,404, 
23,460) 29.5 (24.7, 31.6) 19.8 (− 0.9, 46.7)
Iraq 903 (753, 1,066) 2.8 (2.4, 3.3) − 3.4 (− 35.3, 35.2) 229 (196, 253) 0.9 (0.8, 1)
− 16.2 (− 42.3, 
10.9)
8,697 (7,402, 
9,922) 26.4 (22.5, 29.4)
− 12.9 (− 40.5, 
18.6)
Jordan 190 (155, 229) 2.6 (2.1, 3.1) 49 (11.5, 97.8) 57 (47, 68) 1 (0.8, 1.2) 62.1 (20.4, 106.7)
1797 (1,483, 
2098) 24.5 (20.1, 28.8) 35.6 (2.8, 75.2)
Kuwait 83 (69, 101) 2.6 (2.2, 3.1) 5.6 (− 12.7, 27.6) 24 (21, 28) 1 (0.8, 1.1) 4.2 (− 11.1, 20.9) 777 (672, 918) 24.8 (21.5, 29.1) − 3.8 (− 18.8, 13.6)
Lebanon 217 (180, 253) 3.4 (2.8, 3.9) 55.2 (19, 108.2) 78 (60, 91) 1.3 (1, 1.5) 51.3 (19.2, 99.2) 2044 (1675, 2,390) 31.8 (25.4, 37.2) 41.4 (11, 87.1)
Libya 238 (191, 293) 4.5 (3.6, 5.5) 53.3 (9.2, 120.9) 74 (59, 91) 1.7 (1.3, 2.1) 42.9 (4.2, 108.7) 2,230 (1781, 2,734) 42.3 (33.9, 51.6) 37.3 (0.6, 97)
Morocco 622 (491, 763) 1.8 (1.5, 2.3) 49.9 (12.1, 108.1) 201 (162, 244) 0.6 (0.5, 0.8) 42.3 (7.8, 95.6)
5,630 (4,531, 
6,841) 16.7 (13.5, 20.2) 33.7 (1.7, 80.5)
Palestine 139 (101, 166) 4.2 (3.1, 4.9) 20.6 (− 14.6, 69.5) 35 (28, 40) 1.4 (1.1, 1.6) 21.6 (− 9.8, 61.1)
1,247 (898, 
1,426) 37 (28.5, 42.1) 7.8 (− 21.7, 46.3)
Oman 70 (55, 88) 2.6 (2, 3.3) 82 (33.4, 150.4) 20 (15, 24) 1 (0.8, 1.2) 82.1 (32.4, 151.9) 660 (525, 823) 25.1 (19.5, 31.1) 66.2 (23.7, 126.4)
Qatar 42 (31, 54) 3.2 (2.4, 4.1) − 44.3 (− 65.1, − 3.4) 12 (9, 15) 1.4 (1, 1.7)
− 49.4 (− 67.5, 
− 10.8) 404 (298, 525) 30.9 (23.1, 38.6)
− 48.8 (− 68, 
− 11.2)
Saudi Arabia 688 (544, 888) 3.2 (2.6, 4) 133.5 (65.8, 277) 200 (162, 253) 1.3 (1.1, 1.6) 138.7 (65.6, 279.1)
6,484 (5,204, 
8,169) 30.5 (24.7, 37.7) 111 (48.8, 227)
Sudan 702 (491, 975) 2.6 (1.8, 3.5) 30 (− 17.1, 95.2) 171 (127, 230) 0.8 (0.6, 1.1) 40.7 (5.6, 99.7) 6,776 (4,822, 9,406) 23.6 (17.4, 31.7)
20.8 (− 18.7, 
75.4)
Syria 311 (247, 387) 2.1 (1.7, 2.6) 47.1 (7.2, 103.6) 96 (77, 120) 0.7 (0.6, 0.9) 40.2 (3.6, 93.8) 2,903 (2,324, 3,566) 19.6 (15.8, 24) 33 (− 3.9, 81.1)
Tunisia 271 (213, 339) 2.2 (1.8, 2.8) 25.1 (− 9.8, 84.8) 97 (76, 121) 0.8 (0.7, 1) 24.7 (− 9.4, 89.4) 2,336 (1844, 2,914) 19.3 (15.3, 24)
11.5 (− 18.9, 
60.7)
Turkey 3,928 (3,318, 4,480) 4.5 (3.8, 5.2) 0.6 (− 25.1, 38.3)
1,351 (1,155, 
1534) 1.6 (1.3, 1.8) 3.1 (− 19.8, 35.7)
36,891 (30,965, 
41,441) 42.9 (36.1, 48.2) − 9.1 (− 33, 24.2)
United Arab 
Emirates 352 (204, 603) 5.4 (3, 9.4) 74 (14.1, 172.9) 83 (46, 145) 2 (1, 3.5) 63.3 (6.2, 152.8)
3,294 (1917, 
5,569) 52.4 (29.2, 89.3) 58.2 (3.2, 146.3)
Yemen 397 (257, 632) 2.1 (1.4, 3.2) 42.8 (− 17.5, 163.9) 97 (65, 148) 0.7 (0.4, 1)
43.9 (− 10.1, 
141)
3,697 (2,462, 
5,891) 18.7 (12.4, 28.7)
26.5 (− 26.7, 
129.5)
South Asia 27,980 (25,445, 29,678) 1.9 (1.7, 2) 48.3 (21.9, 78.6)
8,316 (7,511, 
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Bangladesh 1990 (1,390, 2,502) 1.5 (1, 1.8) − 2.3 (− 25.3, 35) 578 (412, 714) 0.5 (0.3, 0.6)
− 5.4 (− 23.3, 
18.1)
18,172 (12,854, 
22,378) 13.4 (9.5, 16.4)
− 10.3 (− 30.4, 
21.1)
Bhutan 14 (10, 19) 2.1 (1.5, 2.7) 22 (− 17, 88.4) 4 (3, 6) 0.7 (0.5, 1) 24.7 (− 10.7, 77.4) 130 (95, 171) 18.7 (13.6, 24.6)
11.6 (− 23.2, 
72.1)
India 22,225 (20,048, 23,856) 1.9 (1.7, 2) 51.6 (22.7, 83)
6,757 (6,142, 




16.7 (15.1, 17.8) 35.7 (8.5, 63.2)
Nepal 416 (278, 630) 1.8 (1.2, 2.7) 49.9 (7.1, 100.6) 132 (90, 198) 0.6 (0.4, 0.9) 49.8 (8, 98.5) 3,765 (2,545, 5,691) 15.8 (10.7, 23.8) 35.2 (− 0.3, 76.9)
Pakistan 3,335 (2,562, 4,236) 2.2 (1.8, 2.8)
74.5 (31.3, 








2,285) 3.3 (2.9, 3.6) 25.2 (13, 37) 627 (559, 685) 1.1 (1, 1.2) 24.9 (13.4, 39.6)
19,099 (16,966, 
21,292) 30.3 (26.9, 33.5) 14.7 (3.7, 24.8)
Botswana 47 (35, 61) 2.8 (2.2, 3.6) 46.2 (10.4, 92.3) 14 (10, 17) 1 (0.8, 1.3) 34 (2.5, 74.2) 428 (318, 550) 25.8 (19.6, 32.7) 27 (− 2, 65.8)
Lesotho 51 (38, 64) 3.6 (2.7, 4.4) 94.2 (40.8, 169.2) 14 (11, 17) 1.2 (0.9, 1.4) 64.4 (23.9, 125) 469 (361, 578) 32.5 (25, 40) 68.8 (22.8, 135.6)
Namibia 40 (33, 49) 2.4 (2, 2.8) 26 (− 4.1, 62) 12 (10, 14) 0.8 (0.7, 1) 15.2 (− 9.4, 42.4) 382 (317, 455) 22.1 (18.6, 25.9) 14.5 (− 11.9, 46)
South Africa 1679 (1,478, 1903) 3.5 (3.1, 3.9) 18 (5.5, 30.3) 527 (465, 585) 1.2 (1.1, 1.3) 22.2 (10.5, 37.1)
15,551 (13,664, 
17,632) 32.3 (28.3, 36.4) 8.6 (− 3.1, 19.5)
Swaziland 31 (23, 42) 4.3 (3.1, 5.7) 51.4 (11.9, 107.8) 9 (6, 12) 1.4 (1.1, 1.9) 32.9 (1.6, 81.3) 302 (226, 404) 40.4 (30, 54.6) 38.8 (5.8, 90.4)




10,332) 2.9 (2.5, 3.4) 33.3 (5.3, 67.6)
1956 (1696, 
2,265) 0.9 (0.8, 1.1) 25.3 (1.7, 52.1)
83,548 (70,625, 
98,563) 26.4 (22.8, 30.7) 19.8 (− 5.4, 49.1)
Benin 285 (205, 387) 3.8 (2.8, 4.9) 81 (36.4, 137.6) 65 (49, 84) 1.2 (0.9, 1.5) 58.8 (22.9, 110.2)
2,709 (1986, 
3,695) 34.1 (25.8, 44.8) 61.8 (23.1, 111.2)
Burkina Faso 487 (335, 702) 3 (2.2, 4) 61.3 (20, 121.8) 97 (73, 128) 0.9 (0.7, 1.1) 36.8 (3, 79.5) 4,535 (3,183, 6,465) 26.8 (20.1, 35.4) 46.4 (9.8, 94.6)
Cameroon 794 (582, 1,105) 4.6 (3.4, 6.1) 53.5 (16.8, 99.7) 191 (142, 252) 1.5 (1.1, 1.9) 36.4 (5.7, 74) 7,482 (5,494, 10,131) 42 (30.9, 55.8) 39.6 (5.6, 79.2)
Cape Verde 26 (22, 32) 5.6 (4.6, 6.8) 85.1 (38, 153.5) 7 (6, 9) 1.6 (1.4, 2) 76.1 (38.4, 149) 252 (213, 301) 53.7 (45.6, 64) 63.9 (24.1, 120.3)
Chad 302 (209, 433) 2.7 (2, 3.4) 77.1 (36.2, 129.1) 59 (43, 76) 0.8 (0.6, 1) 51 (20.7, 87)
2,888 (2010, 
4,018) 24.3 (18.1, 30.7) 60.6 (23.3, 102.9)
Cote d’Ivoire 322 (248, 410) 2.3 (1.8, 2.8) 56.5 (21.3, 98.1) 82 (65, 101) 0.8 (0.6, 0.9) 40.4 (10.5, 76.2) 2,948 (2,301, 3,739) 20.2 (16.1, 24.9) 41.5 (10.9, 78.2)
The Gambia 31 (23, 40) 2.5 (1.9, 3.2) 54.3 (14.1, 99.2) 9 (7, 11) 0.9 (0.7, 1.1) 41.3 (6.8, 80.4) 284 (209, 366) 22.9 (17.5, 28.6) 37.5 (3.5, 76.2)
Ghana 702 (525, 946) 3.1 (2.5, 4) − 4.6 (− 31.1, 60.1) 160 (129, 198) 0.9 (0.8, 1.2) 6.1 (− 16.8, 53.9)
6,442 (4,864, 
8,547) 28 (22.3, 34.8)
− 13.5 (− 36.4, 
43.8)
Guinea 202 (149, 269) 2.7 (2.1, 3.7) 37.5 (1.3, 91.6) 53 (42, 72) 0.9 (0.7, 1.3) 32.3 (1, 87.5) 1882 (1,407, 2,459) 24.3 (19, 32.9) 21.9 (− 8.1, 68.1)
Guinea‐Bissau 50 (35, 70) 4.3 (3.1, 6) 61.7 (24.7, 109.6) 11 (8, 15) 1.3 (0.9, 1.8) 42.8 (13.1, 76) 455 (326, 644) 38.1 (27.1, 53.2) 45 (12.4, 85.7)
Liberia 95 (63, 140) 3.2 (2.3, 4.7) 28.2 (− 7.6, 71.4) 23 (16, 32) 1.1 (0.8, 1.5) 24.4 (− 1.9, 57) 896 (604, 1,316) 29.4 (20.9, 41.5) 14.2 (− 18, 52.7)
Mali 373 (267, 524) 2.5 (1.9, 3.1) 32.6 (− 2.3, 78.5) 80 (62, 100) 0.8 (0.6, 1) 24.7 (− 2, 56.9) 3,581 (2,604, 4,984) 22.6 (17.6, 28.3) 21.1 (− 9.4, 59)
Mauritania 100 (74, 133) 3.8 (2.9, 4.9) 54.9 (12.3, 108.1) 26 (21, 34) 1.2 (1, 1.6) 39.7 (4.6, 82.9) 909 (681, 1,189) 33.6 (25.8, 43) 40.5 (1.9, 86)
Niger 369 (228, 555) 2.3 (1.5, 3.1) 18 (− 16.8, 62.4) 70 (46, 93) 0.7 (0.5, 0.9) 11.9 (− 11.4, 40.6)
3,510 (2,253, 
5,091) 20.8 (13.5, 27.5) 5.2 (− 27.2, 42.1)
Nigeria 4,062 (2,932, 5,453) 2.7 (2, 3.7)
24.3 (− 19.4, 
94.6) 865 (652, 1,147) 0.8 (0.6, 1.1)
16.7 (− 22.2, 
69.2)
38,796 (28,645, 
51,849) 24.7 (18.6, 33)
11.3 (− 27.8, 
69.7)
Sao Tome and 
Principe 5 (3, 9) 3.4 (2.2, 4.8)
36.5 (− 18.3, 
113.3) 1 (1, 2) 1 (0.7, 1.3) 50.2 (8.6, 104.2) 56 (31, 95) 33.3 (20.6, 47.9)
19.7 (− 27.9, 
88.5)
Senegal 331 (241, 448) 3.3 (2.5, 4.3) 54.1 (9.6, 105.4) 85 (65, 109) 1.1 (0.8, 1.4) 39.5 (3, 79.7) 3,085 (2,249, 4,181) 30 (22.6, 38.7) 37.3 (− 3.1, 83)
Sierra Leone 164 (122, 215) 3 (2.4, 3.7) 55.9 (12.8, 109.7) 37 (30, 45) 0.9 (0.8, 1.1) 44.2 (9.3, 94.8)
1566 (1,172, 
2017) 27.4 (21.7, 33.6) 38.1 (− 0.8, 82.3)




8,386) 2.5 (2.1, 2.9) 7.7 (− 29.3, 63.9)
1,467 (1,259, 
1696) 0.8 (0.7, 0.9) 5.2 (− 25.8, 38.7)
66,589 (54,910, 
79,913) 22.8 (19.5, 26.4)
− 2.4 (− 37.5, 
50.4)
Burundi 165 (120, 224) 2.1 (1.6, 2.6) − 10.4 (− 37.3, 35.2) 33 (27, 41) 0.6 (0.5, 0.8)
− 12.9 (− 35, 
21.1)
1613 (1,195, 
2082) 19.4 (15.5, 23.4)
− 17.6 (− 40.9, 
23.5)
Comoros 14 (9, 19) 2.4 (1.7, 3.2) 10.8 (− 28.9, 55.9) 4 (3, 5) 0.8 (0.6, 1) 6.4 (− 29.5, 42.8) 128 (85, 176) 22.4 (15.6, 29.4)
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− 30 to 16)], Southern Latin America [− 7% (95% UI: − 18 to 30)] and High-income North America [− 1% (95% 
UI: − 6 to 11)], which all showed non-significant decreases in age-standardised death rates (Table 1). The percent-
age change in age-standardised incidence and death rates, by GBD region and by sex, are presented in Fig. 2a, b.
In 1990 the highest number of incident cases were found in Western Europe [44,006 (95% UI: 38,633–45,652)], 
High-Income North America [39,473 (95% UI: 35,501–40,625)] and East Asia [25,170 (95% UI: 22,570–30,076)]. 
In 2017, the highest numbers were found in Western Europe 72,675 (95% UI: 65,477–76,756)], High-Income 
North America [68,842 (95% UI: 65,663–74,202)] and East Asia [52,290 (95% UI: 46,830–56,228)] (Fig. 3a). In 
1990, the number of deaths were found to be highest in Western Europe [18,583 (95% UI: 16,369–19,093)], High-
Income North America [11,117 (95% UI: 10,077–11,359)] and Eastern Europe [8,812 (95% UI: 7,751–9,794)]. 
In 2017, the highest number of deaths were found in Western Europe [30,325 (95% UI: 27,097–31,837)], High-
Income North America [19,048 (95% UI: 18,297–20,091)] and East Asia [18,634 (95% UI: 16,488–19,986)] 
(Fig. 3b).
National level.  In 2017, the age-standardised incidence rates ranged from 1.5 to 15.8 per 100,000 people 
for the 195 countries studied. Uruguay [15.8 (95% UI: 13.6–19.0)], Slovakia [14.1 (95% UI: 7.7–16.5)] and the 
Czech Republic [13.1 (95% UI: 10.7–14.5)] had the highest age-standardised incidence rates. In contrast, Bang-
ladesh [1.5 (95% UI: 1.0–1.8)], Kenya [1.5 (95% UI: 1.1–1.9)] and Nepal [1.8 (95% UI: 1.1–2.6)] had the lowest 
age-standardised incidence rates (Fig. 4). The age-standardised death rate also varied substantially by country, 
ranging from 0.47 to 5.6 per 100,000 people. The Czech Republic [5.6 (95% UI: 4.6–6.1)], Uruguay [5.5 (95% 
UI: 4.8–6.5)] and Iceland [5.2 (95% UI: 4.8–5.7)] had the highest age-standardised death rates, while Bangladesh 



















Djibouti 25 (16, 38) 3.2 (2.1, 4.6) 42.7 (− 9.3, 122.8) 6 (4, 9) 1 (0.7, 1.4) 39.2 (− 4.6, 98.1) 237 (153, 357) 29.3 (19.3, 42.2) 28 (− 16.2, 94.2)
Eritrea 132 (69, 207) 3.3 (1.8, 4.6) 36.4 (− 22.2, 123) 27 (15, 38) 1 (0.5, 1.3) 25 (− 23.7, 78)
1,256 (646, 
1944) 30.4 (16.6, 43.1)
22.9 (− 31.2, 
100.3)
Ethiopia 1859 (1,299, 2,448) 2.7 (1.9, 3.3)
− 16.6 (− 52.4, 
69.6) 406 (296, 488) 0.9 (0.6, 1.1)
− 11.9 (− 47.5, 
52.2)
17,477 (12,846, 
21,960) 24.5 (17.7, 29.4)
− 24.3 (− 57.5, 
54.9)
Kenya 447 (321, 565) 1.5 (1.1, 1.9) 29.5 (2.5, 52.2) 115 (86, 146) 0.5 (0.4, 0.7) 17.8 (− 4, 38) 4,152 (2,997, 5,301) 13.9 (10.3, 17.7) 17.2 (− 7.6, 36.9)
Madagascar 349 (229, 496) 1.9 (1.3, 2.4) 4.7 (− 24.5, 45.9) 73 (52, 95) 0.6 (0.4, 0.7) 3.3 (− 21.5, 33.2) 3,362 (2,261, 4,622) 17.3 (12.2, 22.3)
− 6.4 (− 30.1, 
28.4)
Malawi 380 (246, 597) 2.8 (2.1, 3.7) 7.3 (− 41.6, 130.8) 80 (58, 102) 0.8 (0.7, 1) 6.8 (− 28.9, 74.4)
3,713 (2,417, 
5,566) 26.6 (19.5, 34.2)
− 2.4 (− 46.6, 
105)
Mozambique 447 (287, 662) 2.4 (1.8, 3.2) 27.3 (− 12.3, 79.5) 103 (74, 135) 0.8 (0.6, 1.1) 22.6 (− 7.8, 77)
4,680 (2,995, 
6,772) 22.8 (16.6, 29.9)
11.9 (− 24.4, 
55.1)
Rwanda 215 (138, 324) 2.3 (1.6, 3.1) − 2.1 (− 40.2, 67.2) 48 (34, 64) 0.7 (0.5, 0.9)
− 5.6 (− 37.9, 
38.5)
2080 (1,374, 
3,104) 21.2 (15, 28.6)
− 9.3 (− 44.8, 
50.3)
Somalia 324 (182, 510) 2.7 (1.7, 3.8) 18.5 (− 32.1, 139) 66 (40, 96) 0.8 (0.5, 1.1) 11.3 (− 28, 82.7)
3,160 (1721, 
5,024) 24.8 (15.2, 35.4)
6.1 (− 38.9, 
120.8)
South Sudan 236 (145, 366) 3.1 (2, 4.7) 32.4 (− 12.2, 114.5) 46 (30, 69) 0.9 (0.6, 1.4) 14.5 (− 19, 68.3)
2,303 (1,461, 
3,554) 28.9 (18.9, 43.6)
19.2 (− 17.9, 
88.6)
Tanzania 1,302 (927, 1824) 2.9 (2.2, 3.8)
39.8 (− 4.6, 
120.1) 260 (202, 331) 0.8 (0.7, 1)
22.3 (− 10.4, 
69.9)
12,521 (9,275, 
16,959) 26.8 (20.6, 34) 26 (− 13.7, 95.2)
Uganda 647 (440, 944) 2.2 (1.7, 2.9) 51.9 (8.7, 106.5) 126 (96, 163) 0.7 (0.5, 0.8) 39.1 (7.6, 79.3) 6,378 (4,398, 9,152) 20.9 (15.9, 26.4) 39.3 (− 1.1, 90.3)
Zambia 365 (259, 510) 3 (2.2, 3.8) 0.8 (− 30.5, 50.6) 74 (56, 93) 0.9 (0.7, 1.2) − 3.5 (− 27.2, 23.9)
3,486 (2,588, 




2,726) 2.7 (2.2, 3.3)
12.8 (− 18.4, 
49.9) 494 (414, 595) 0.8 (0.7, 1.1) 7.2 (− 17.9, 31.6)
20,758 (16,716, 
25,241) 24.5 (20.5, 29.5) 1.6 (− 25.7, 36)
Angola 630 (467, 877) 3.5 (2.7, 4.4) 18.7 (− 20.6, 89.1) 140 (112, 177) 1.1 (0.9, 1.4) 23 (− 10.5, 68.8)
5,998 (4,426, 
8,323) 31.8 (25.2, 39.8) 6.6 (− 28, 65.5)
Central African 
Republic 97 (61, 143) 2.9 (2.1, 4)
19.2 (− 15.4, 
70.8) 21 (15, 28) 0.9 (0.7, 1.1) 3.3 (− 23.9, 37.4) 930 (601, 1,330) 27.2 (19.6, 36.2) 7.3 (− 22.1, 50.8)
Congo 133 (93, 188) 3.9 (2.8, 5.3) 26.2 (− 21.2, 78.5) 33 (24, 43) 1.3 (0.9, 1.6)
21.6 (− 19.3, 
62.2)
1,203 (865, 
1637) 35.5 (25.5, 46.4) 12.2 (− 28.7, 58)
DR Congo 1,243 (902, 1,720) 2.2 (1.6, 3.1) 4.5 (− 31.8, 48) 277 (203, 373) 0.7 (0.5, 1) − 3.4 (− 33.4, 27)
11,836 (8,923, 
15,474) 20.5 (15, 27.7) − 5.5 (− 37, 34.7)
Equatorial 
Guinea 31 (18, 51) 4.5 (2.8, 6.9)
51.9 (− 8.2, 
156.1) 8 (5, 12) 1.6 (1, 2.3) 61.9 (7.3, 156.9) 296 (167, 502) 41.4 (25.1, 64.6)
37.2 (− 12.7, 
128.5)
Gabon 52 (40, 70) 4.2 (3.3, 5.5) 46.2 (1.4, 94.2) 15 (12, 20) 1.4 (1.1, 1.8) 36.7 (0.5, 81.4) 496 (376, 668) 39.3 (30.5, 51.8) 31.8 (− 7.4, 75.9)
Table 1.  Incidents, Deaths, and DALYs for kidney cancer in 2017 and the percentage change in age-
standardized rates by location. PCs percentage changes, ASRs age-standardised rates, DALYs disability adjusted 
life years, UI uncertainty interval.
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[0.47 (95% UI: 0.34–0.58)], Kenya [0.52 (95% UI: 0.39–0.66)] and Madagascar [0.58 (95% UI: 0.41–0.73)] had 
the lowest rates (Fig. 5).
The percentage change in age-standardised incidence rates, from 1990 to 2017, differed substantially between 
countries, with Armenia [284.2% (95% UI: 115.0–390.1)], Belarus [241.0% (95% UI: 88.1–324.9)] and Latvia 
[216.3% (95% UI: 78.8–293.8)] showing the largest increases. In contrast, Qatar [− 44.3% (95% UI: − 65.1 to 
− 3.4)] Bermuda [− 43.9% (95% UI: − 54.2 to − 11.8)] and Trinidad and Tobago [− 36.9% (95% UI: − 53.1 to 
30.7)] showed decreasing trends, although not all of these were statistically significant. The percentage change 
in age-standardised death rates (from 1990 to 2017) also differed between countries. The largest increases were 
seen in Armenia [396.6% (95% UI: 187.3–526.2)], Belarus [277.5% (95% UI: 114.9–359.9)] and Latvia [256.3% 
(95% UI: 113.4–336.1)]. In contrast, the largest decreases during this period were found in Qatar [− 49.4% (95% 
UI: − 67.5 to − 10.8)], Bermuda [− 43.5% (95% UI: − 51.5 to − 15.4)] and Trinidad and Tobago [− 41.4% (95% 
a
b
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UI: − 54.7 to 10.2)] (Table 1). However, it is important to again note that some of these increases or reductions 
were not statistically significant.
Age and sex patterns.  Sex differences in the incident rates first appeared in the 35–39 age group and 
increased up to the oldest age group (95+). The number of incidents was also higher in males, from the 30–34 
age group up to the 85–89 age group, with a peak being seen in the 65–69 age group (Fig. 6). The death rate was 
also higher in males, than in females, in all age groups. The number of deaths was also higher in males in all age 
groups, except the 1–4 and 95+ age groups (Online Appendix Fig. 1). However, the pattern for DALY rates was 
slightly different, such that the trend started declining after 80–84 for males and 85–89 for females. The number 
of DALYs was also higher in males, in most of the age groups, except the 5–9, 10–14, 90–94 and 95+ age groups. 
The number of DALYs peaked in the 60–64 age group (Online Appendix Fig. 2). The YLL rate peaked in the 
80–84 age group, which comprised a large proportion of the DALYs (Online Appendix Fig. 3).
a
b
Figure 2.  The percentage change in the age-standardised incidence (a) and death (b) rates of kidney cancer 
from 1990 to 2017 for the 21 GBD regions by sex.
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Burden of kidney cancer by SDI.  At the regional-level, the age-standardised DALY rate increased up to 
an SDI of approximately 0.74 and then decreased with increasing SDI values (Fig. 7). The global age-standardised 
DALY rate was initially higher than expected, but then the rate fell below the expected level for the last 14 years. 
High-income Asia–Pacific was the only region in the GBD high-income super regions that had a lower than 
expected DALY rate across the entire measurement period. For the GBD super-regions of Central Europe, East-
ern Europe and Central Asia, only Eastern Europe had a higher than expected DALY rate for the entire measure-
ment period, while Central Europe had a higher than expected level for the last 13 years. From the Latin America 
and Caribbean super-region, only Southern and Central Latin America had higher than expected DALY rates 
across the entire measurement period. In the Sub-Saharan Africa super-region, only Southern Sub-Saharan 
Africa was found to have a lower than expected DALY rate for the entire measurement period. In the Southeast 
Asia, East Asia and Oceania super-regions, only Southeast Asia and East Asia had a lower than expected DALY 
rate from 1990 to 2017, but Oceania was lower than expected during the last 3 years of the measurement period. 
The South Asia region had a lower than expected DALY rate for the entire measurement period, while the North 
Africa and Middle East region was lower for most of the measurement period (from 1992 to 2017) (Fig. 7). 
Figure 8 presents the country-level age-standardised DALY rates and its expected relationship with SDI. The 
expected patterns were non-linear in nature, peaking at an SDI of 0.84. However, there were large national dif-
ferences in age-standardised DALY rates. Uruguay, the Czech Republic, Lithuania, Ukraine, Iceland, Greenland 
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and many other countries showed higher than their expected DALY rates, whereas Singapore, Kuwait, China, 
Algeria, Morocco and many other countries had much lower than expected DALY rates, based only on their SDI.
Risk  factors.  Globally, 18% of kidney cancer DALYs was attributable to high BMI in both sexes (Male: 
16.5%; Female: 22.1%). The proportion of kidney cancer DALYs there were attributable to high BMI ranged 
from 7.1% in Eastern Sub-Saharan Africa to 29.2% in High-income North America. Furthermore, 16.6% of 
kidney cancer DALYs was attributable to smoking in both sexes, but this burden was higher in males (21.6%) 
than females (7.3%). The smoking-attributable burden also differed across GBD regions, ranging from 3.9% in 
Western Sub-Saharan Africa to 22.9% in Eastern Europe. Finally, the burden of kidney cancer attributable to 
occupational exposure to trichloroethylene was negligible (Fig. 9).
Discussion
This study reported the incidence, mortality, and DALYs for kidney cancer in 195 countries from 1990 to 2017. 
Globally, the age-standardised incidence and death rates have increased while the DALY rates have declined, 
although neither of these changes were statistically significant. Our results show that there has been little or no 
progress in reducing the burden of Kidney cancer over the past 28 years and we call for renewed efforts to reduce 
the burden of this disease. GLOBOCAN estimated that there were 403,262 (95% UI: 387,315–419,865) incident 
cases of kidney cancer globally in 2018, which is close to our estimate of 393,043 (95% UI: 371,162–404,595) in 
2017. However, GLOBOCAN estimated that there were 175,098 deaths (95% UI: 166,193–184,480), which is 
much higher than the 138,526 (95% UI: 128,656–142,522) estimated in the present  research9. There are several 
reasons for these differences, which may related to the data sources and/or different methodological approaches. 
The GBD methodology considers all causes of deaths in each run, whereas GLOBOCAN only provides cancer 
mortality.
Previous research has found that more developed countries have a higher incidence of kidney cancer than less 
developed  countries8, which was also confirmed in the present study. The association that development level has 
with kidney cancer incidence and mortality has only been investigated in a small number of studies and these 
studies only used data from selected countries, meaning that their results must be interpreted with  caution8,17. 
There are also a number of other problems with the previous research on this topic. For example, previous 
Figure 4.  Age-standardised incidence rate (per 100,000 population), by country, for 2017. ATG Antigua and 
Barbuda, VCT Saint Vincent and the Grenadines, BRB Barbados, COM Comoros, DMA Dominica, GRD 
Grenada, MDV Maldives, MUS Mauritius, LCA Saint Lucia, TTO Trinidad and Tobago, TLS Timor-Leste, 
SYC Seychelles, MLT Malta, SGP Singapore, MHL Marshall Islands, KIR Kiribati, SLB Solomon Islands, FSM 
Federated States of Micronesia, VUT Vanuatu, WSM Samoa, FJI = Fiji, TON Tonga. Maps were generated using 
R software version 3.5.2. (R Core Team (2019). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. https ://www.R-proje ct.org/).
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Figure 5.  Age-standardised death rate (per 100,000), by country, for 2017. ATG Antigua and Barbuda, VCT 
Saint Vincent and the Grenadines, BRB Barbados, COM Comoros, DMA Dominica, GRD Grenada, MDV 
Maldives, MUS Mauritius, LCA Saint Lucia, TTO Trinidad and Tobago, TLS Timor-Leste, SYC Seychelles, MLT 
Malta, SGP Singapore, MHL Marshall Islands, KIR Kiribati, SLB Solomon Islands, FSM Federated States of 
Micronesia, VUT Vanuatu, WSM Samoa, FJI Fiji, TON Tonga. Maps were generated using R software version 
3.5.2. (R Core Team (2019). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. https ://www.R-proje ct.org/).
Figure 6.  Global number of incidents and age-standardised incidence rate of kidney cancer per 100,000 
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research found that the incidence rate of kidney cancer was twice as high in developed countries as in developing 
 countries8. However, this research only compared two states of development (developed vs. developing) and they 
did not measure each country’s level of development using the SDI. In fact, using only two categories of develop-
ment leads to information loss, which means that accurate and precise patterns may not be produced. Secondly, 
previous research determined development status using the Human Development Index (HDI), which is prob-
lematic as one of the HDI’s components (life expectancy) is associated with health. Therefore, the association that 
development status has with kidney cancer may have previously been over-estimated8. In order to address this 
issue, in GBD 2017 we used the SDI, which does not include any health-related components. Thirdly, consider-
ing the association between the variables to be linear may be  inaccurate8. Hence, we examined the non-linear 
association between SDI and kidney cancer burden, in order to determine the shape of the association. Finally, 
Figure 7.  Age-standardised DALY rates for kidney cancer for the 21 Global Burden of Disease regions by 
Socio-demographic Index, 1990–2017; Expected values based on Socio-demographic Index and disease rates 
in all locations are shown as the black line. For each region, points from left to right depict estimates from each 
year from 1990 to 2017. DALY disability-adjusted life-year.
Figure 8.  Age-standardised DALY rates of kidney cancer in 195 countries and Socio-demographic Index, 2017; 
Expected values are shown as the black line. DALY disability-adjusted life-year.
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previous research examined the association between the HDI of a specific year (e.g., 2000) with the incidence 
and mortality rates of a different year (e.g., 2012)8. In this study, we examined the same years.
There are a number of possible reasons for the higher burden of kidney cancer in developed countries. Firstly, 
the prevalence of risk factors, such as smoking, high BMI and low physical activity and hypertension may be 
higher in developed countries than in developing  regions8. Secondly, the increases in the incidence of kidney 
cancer could also be partly due to improvements in the early detection of cancer using imaging procedures, such 
as ultrasonography, computed tomography, and magnetic resonance imaging in high income  countries3. Perhaps 
the increases in the incidences of kidney cancer may be due to exposure to occupational and environmental risk 
factors, such as trichloroethylene, cadmium, arsenic, radon and nitrate. Although we know exposure to these 
risk factors have declined in the developed world, there is no evidence to suggest this same pattern has been 
replicated in the developing  world3,5,18.
Although a number of risk factors have found to be associated with kidney cancer, the attributable burden 
was only calculated for those risk factors that had robust evidence of their relationship with kidney  cancer10. 
Therefore, the attributable burden was calculated for two life style risk factors (smoking and high body mass 
index) and one environmental and occupational risk factor (occupational exposure to trichloroethylene).
High BMI (overweight/obesity) is one of the important risk factors, contributing 18.5% to the burden of 
kidney cancer in the population. Previous research has found that the prevalence of obesity has continuously 
increased in most countries during the period 1990–2015 and has doubled in more than 70  countries19. Moreo-
ver, in many countries the rate of increase in childhood obesity has been greater than the rate of increase among 
 adults19. There are a number of approaches that can be taken to reduce the prevalence of being overweight and 
obese and to thereby reduce the burden of this disease. These measures should include a ban on advertising 
unhealthy foods, improving school meals, taxation, subsidies, and incentives to increase the production of 
healthy  foods20.
Our study also found that smoking contributes 16.6% to the burden of kidney cancer (both sexes) and reduc-
ing exposure to this risk factor could play an important role in decreasing the burden of this disease. A study of 
the global progress in reducing the prevalence of smoking has reported heterogeneous findings, according to 
country, development status, and sex. Globally, the age-standardised prevalence rate of daily smoking declined 
by 28.4% and 34.4%, respectively, among men and women from 1990 to  201521. There is a need to achieve 
greater success in the control of tobacco smoking through the use of effective, comprehensive, and adequately 
implemented and enforced policies.
The third risk factor assessed in our study was exposure to Trichloroethylene, which is usually used as a 
metal cleaner and  degreaser15. The burden of kidney cancer that was attributable to occupational exposure to 
trichloroethylene was found to be 0.1%. The attributable burden of this risk factor is negligible, as the popula-
tions’ exposure is very low. A meta-analysis found that occupational exposure to trichloroethylene increased 
the risk of kidney cancer by 32%22.
Physical activity and alcohol consumption have also been considered to be lifestyle risk factors. A meta-
analysis found a negative association between physical activity and kidney  cancer23, which was also confirmed in 
a pooled analysis of cohort  studies24. However, research has also shown that prolonged sitting does not increase 
kidney cancer among men and  women25. Therefore, it is not entirely clear how physical activity changes the risk 
Figure 9.  Percent of kidney cancer DALYs attributable to risk factors for the 21 Global Burden of Disease 
regions in 2017. DALY disability-adjusted life-year.
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of kidney cancer and its association with kidney cancer has not been examined independently from high body 
mass index and  hypertension5.
Alcohol consumption is another potential risk factor that has been extensively studied. Two meta-analyses26,27 
have found there to be an inverse relationship between alcohol consumption and the risk of kidney cancer, and 
these findings have been confirmed by large scale prospective  studies28,29. All of the aforementioned studies 
reported a lower risk for drinkers, compared to non-drinkers or light drinkers. GBD 2017 did not calculate the 
burden of kidney cancer attributable to alcohol consumption, but this addition has been suggested for future 
GBD cycles, as there is sufficient evidence of the association between these two variables.
Although the association between diet and kidney cancer has been examined in previous research, the evi-
dence is not  robust5. Most studies have reported no association between fruit and vegetable intake and the risk 
of kidney cancer, and nutrient specific associations have not been  reported5.
Medical history, including hypertension, chronic kidney disease, kidney stones and diabetes mellitus have 
also been found to be associated with kidney  cancer5,6. Several studies have reported that hypertension increases 
the risk of kidney cancer and have reported dose–response relationships between blood pressure and kidney 
cancer  risk30,31. This risk factor has also been suggested for inclusion in the next cycle of the GBD study. Chronic 
kidney disease has also been found to be a risk factor for kidney  cancer32–34. Furthermore, previous large scale 
 studies35,36 and one meta-analysis37 have found a higher risk of kidney cancer to be associated with kidney stones. 
Finally, previous large scale  studies38,39 and a meta-analysis40 have found diabetes mellitus to be associated with 
a higher risk of kidney cancer.
Considering the evidence reported above, there is sufficient evidence to suggest that the risk of kidney cancer 
is associated with: alcohol consumption, hypertension, chronic kidney diseases, kidney stones and diabetes mel-
litus. These risk factors should all be included into the next cycle of the GBD project to inform public policy and 
health policy makers how much of the kidney cancer burden could be attributed to each of these risk factors. 
However, the evidence for physical activity, diet and several other risk factors are not compelling and further 
research is needed.
The present study provides important information on the proportion of the kidney cancer burden that is 
attributable to modifiable risk factors, such as smoking, high body mass index and occupational exposure to 
trichloroethylene, which can be used for primary prevention purposes. However, the role of other risk factors, 
such as hypertension and diabetes mellitus, should be calculated in future iterations of the GBD project. In 
addition, improvements in diagnostic measures are needed, with the identification of blood- and urine-based 
markers being one approach with considerable  merit5. These improvements are needed to allow earlier detection 
of kidney cancer and thereby a better prognosis for patients.
Strengths and limitations
The present research had a number of limitations. Firstly, it is possible that in some countries the rate of cancer 
detection is low and hence the incidence is lower than reported here. Secondly, some countries do not have the 
vital statistics to capture the causes of death. GBD methodology adjusts for these biases and provides uncertainty 
intervals for all estimates.
conclusions
There has been little or no improvement in the burden of kidney cancer over the last 28 years. Our study provides 
much needed information about the burden of kidney cancer in each country, to enable countries to better plan 
to address their burden and to allocate their limited resources more appropriately. Our results highlight the 
need for renewed efforts to reduce exposure to risk factors and to improve the prevention and early detection 
of this disease.
Received: 12 February 2020; Accepted: 3 August 2020
References
 1. Collaboration GBoDC. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and 
disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA 
Oncol. 5, 1749–1768. https ://doi.org/10.1001/jamao ncol.2019.2996 (2019).
 2. Roth, G. A. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 
1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788. https ://doi.org/10.1016/
S0140 -6736(18)32203 -7 (2018).
 3. Gupta, K. et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer 
Treat. Rev. 34, 193–205 (2008).
 4. Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and 
disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA 
Oncol. https ://doi.org/10.1001/jamao ncol.2018.2706 (2018).
 5. Scelo, G. & Larose, T. L. Epidemiology and risk factors for kidney cancer. J. Clin. Oncol. 36, 3574 (2018).
 6. Chow, W.-H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245–257. https ://doi.
org/10.1038/nruro l.2010.46 (2010).
 7. Znaor, A. et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67, 519–530 (2015).
 8. Wong, M. C. et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci. Rep. 7, 15698 
(2017).
 9. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide 
for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018
19
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13862  | https://doi.org/10.1038/s41598-020-70840-2
www.nature.com/scientificreports/
 10. Stanaway, J. D. et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, 
and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden 
of Disease Study 2017. The Lancet 392, 1923–1994. https ://doi.org/10.1016/S0140 -6736(18)32225 -6 (2018).
 11. Kyu, H. H. et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life 
expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 
2017. Lancet 392, 1859–1922 (2018).
 12. Foreman, K. J. et al. Modeling causes of death: an integrated approach using CODEm. Popul. Health Metrics 10, 1 (2012).
 13. Wang, Y. Smoothing Splines: Methods and Applications (CRC Press, Boca Raton, 2011).
 14. Wang, F. & Xu, Y. Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. Int. J. 
Cancer 135, 1673–1686 (2014).
 15. Smoke, T. & Smoking, I. IARC monographs on the evaluation of carcinogenic risks to humans 1–1452 (IARC, Lyon, 2004).
 16. Kelsh, M. A. et al. Occupational trichloroethylene exposure and kidney cancer: a meta-analysis. Epidemiology 21, 95–102 (2010).
 17. Dy, G. W. et al. Global burden of urologic cancers, 1990–2013. Eur. Urol. 71, 437–446 (2017).
 18. Rusyn, I. et al. Trichloroethylene: mechanistic, epidemiologic and other supporting evidence of carcinogenic hazard. Pharmacol. 
Ther. 141, 55–68. https ://doi.org/10.1016/j.pharm thera .2013.08.004 (2014).
 19. Collaborators, G. O. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377, 13–27 (2017).
 20. Hawkes, C. et al. Smart food policies for obesity prevention. Lancet (London, England) 385, 2410–2421. https ://doi.org/10.1016/
s0140 -6736(14)61745 -1 (2015).
 21. Collaborators, G. B. D. T. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a sys-
tematic analysis from the Global Burden of Disease Study 2015. Lancet (London, England) 389, 1885–1906. https ://doi.org/10.1016/
S0140 -6736(17)30819 -X (2017).
 22. Karami, S. et al. Occupational trichloroethylene exposure and kidney cancer risk: a meta-analysis. Occup. Environ. Med. 69, 858–867 
(2012).
 23. Behrens, G. & Leitzmann, M. The association between physical activity and renal cancer: systematic review and meta-analysis. Br. 
J. Cancer 108, 798–811 (2013).
 24. Moore, S. C. et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. 
Med. 176, 816–825 (2016).
 25. George, S. M. et al. A prospective analysis of prolonged sitting time and risk of renal cell carcinoma among 300,000 older adults. 
Ann. Epidemiol. 21, 787–790 (2011).
 26. Song, D. et al. Alcohol intake and renal cell cancer risk: a meta-analysis. Br. J. Cancer 106, 1881–1890 (2012).
 27. Lee, J. E. et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J. Natl. Cancer Inst. 99, 801–810. 
https ://doi.org/10.1093/jnci/djk18 1 (2007).
 28. Karami, S., Daugherty, S. E. & Purdue, M. P. A prospective study of alcohol consumption and renal cell carcinoma risk. Int. J. 
Cancer 137, 238–242. https ://doi.org/10.1002/ijc.29359 (2015).
 29. Wozniak, M. B. et al. Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and 
nutrition (EPIC). Int. J. Cancer 137, 1953–1966. https ://doi.org/10.1002/ijc.29559 (2015).
 30. Sanfilippo, K. M. et al. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hyperten-
sion (Dallas, Tex: 1979) 63, 934–941. https ://doi.org/10.1161/hyper tensi onaha .113.02953 (2014).
 31. Weikert, S. et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutri-
tion. Am. J. Epidemiol. 167, 438–446. https ://doi.org/10.1093/aje/kwm32 1 (2008).
 32. Lowrance, W. T. et al. CKD and the risk of incident cancer. J. Am. Soc. Nephrol. JASN 25, 2327–2334. https ://doi.org/10.1681/
asn.20130 60604 (2014).
 33. Butler, A. M. et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am. J. Kidney Dis. 
65, 763–772. https ://doi.org/10.1053/j.ajkd.2014.12.013 (2015).
 34. Hofmann, J. N. et al. Chronic kidney disease and risk of renal cell carcinoma: differences by race. Epidemiology (Cambridge, Mass) 
26, 59–67. https ://doi.org/10.1097/EDE.00000 00000 00020 5 (2015).
 35. Chung, S. D., Liu, S. P. & Lin, H. C. A population-based study on the association between urinary calculi and kidney cancer. Can. 
Urol. Assoc. J. Journal de l’Association des urologues du Canada 7, E716-721. https ://doi.org/10.5489/cuaj.366 (2013).
 36. Shih, C. J. et al. Urinary calculi and risk of cancer: a nationwide population-based study. Medicine 93, e342. https ://doi.org/10.1097/
md.00000 00000 00034 2 (2014).
 37. Cheungpasitporn, W. et al. The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis. QJM 
Int. J. Med. 108, 205–212. https ://doi.org/10.1093/qjmed /hcu19 5 (2014).
 38. Harding, J. L. et al. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and 
reverse causation. Diabetes Care 38, 264–270 (2015).
 39. Joh, H. K., Willett, W. C. & Cho, E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 34, 1552–1556. https 
://doi.org/10.2337/dc11-0132 (2011).
 40. Larsson, S. & Wolk, A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54, 
1013–1018 (2011).
Acknowledgements
We would like to thank the Institute for Health Metrics and Evaluation staff and its collaborators who collected 
and made these data publicly available. In addition, we would like to acknowledge the financial support from 
the Social Determinants of Health Research Center at the Shahid Beheshti University of Medical Sciences. GBD 
2017 was funded by the Bill and Melinda Gates Foundation. However, the foundation was not involved in any 
way in the preparation of this manuscript. The present report was also supported by the Social Determinants of 
Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant Number: 17548).
Author contributions
S.S., A.A.K., A.M. and C.F. designed the study. S.S., A.A.-H., M.M.L., A.A.-A. and M.Q. tabulated data and per-
formed the statistical analyses. S.S., A.A.K., M.A.M., M.J.S., M.A. and D.B. drafted the initial manuscript. All 
authors reviewed the drafted manuscript for critical content and all authors approved the final version of the 
manuscript.
Competing interests 
The authors declare no competing interests.
20
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:13862  | https://doi.org/10.1038/s41598-020-70840-2
www.nature.com/scientificreports/
Additional information
Supplementary information  is available for this paper at https ://doi.org/10.1038/s4159 8-020-70840 -2.
Correspondence and requests for materials should be addressed to S.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
